IBI362 has been designed to balance the activation of GLP-1 receptor and glucagon receptor in order to avoid the glucagon receptor-induced hyperglycaemia while maintaining the desired effects of HbA1c reduction and body weight loss. This evidence concerns the gene GLP1R and Hyperglycemia.